StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Pulmatrix stock opened at $1.95 on Thursday. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $2.84. The stock’s fifty day simple moving average is $1.92 and its 200-day simple moving average is $1.89.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported $0.23 earnings per share for the quarter. The company had revenue of $5.89 million for the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- What is MarketRank™? How to Use it
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- What is the Euro STOXX 50 Index?
- Progress Software Stock Back in the Green After Beating Forecasts
- When to Sell a Stock for Profit or Loss
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
